Nicholas Investment Partners, LP Clovis Oncology, Inc. Transaction History

Nicholas Investment Partners, LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2019 Aug 09, 2019	SELL	$12.81 - $25.67 $1.47 Million - $2.94 Million	-114,460 Closed	0 $0
Q1 2019 May 15, 2019	BUY	$17.66 - $30.28 $630,868 - $1.08 Million	35,723 Added 45.37%	114,460 $2.84 Million
Q4 2018 Feb 14, 2019	BUY	$11.63 - $32.67 $915,711 - $2.57 Million	78,737 New	78,737 $1.41 Million
Q4 2017 Feb 14, 2018	SELL	$57.69 - $84.58 $1.44 Million - $2.11 Million	-24,917 Closed	0 $0
Q3 2017 Nov 13, 2017	BUY	$67.17 - $84.81 $1.67 Million - $2.11 Million	24,917	24,917 $2.05 Million

166

Ticker CLVS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 144,480,000
Market Cap $13M
Description
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. In the U.S., the company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or pr...

Get notified when there are updates to the investment portfolio of Nicholas Investment Partners, LP, based on Form 13F filings with the SEC.

Stay updated on Nicholas Investment Partners, LP with notifications on news.